Wonbiogen Co., Ltd. (KOSDAQ:307280)
South Korea · Delayed Price · Currency is KRW 6,550.00
-30.00 (-0.46%)
At close: Jan 23, 2026
Wonbiogen Revenue
Wonbiogen had revenue of 9.22B KRW in the quarter ending September 30, 2025, with 34.33% growth. This brings the company's revenue in the last twelve months to 34.38B, up 17.33% year-over-year. In the year 2024, Wonbiogen had annual revenue of 30.44B with 2.79% growth.
Revenue (ttm)
34.38B
Revenue Growth
+17.33%
P/S Ratio
1.44
Revenue / Employee
446.51M
Employees
77
Market Cap
49.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30.44B | 824.93M | 2.79% |
| Dec 31, 2023 | 29.61B | 2.87B | 10.72% |
| Dec 31, 2022 | 26.75B | 9.03B | 50.94% |
| Dec 31, 2021 | 17.72B | 5.70B | 47.46% |
| Dec 31, 2020 | 12.02B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| KM Corporation | 133.05B |
| JW Shinyak | 76.02B |
| Sewoon Medical | 62.13B |
| CG MedTech | 45.59B |
| OSTEONIC | 42.11B |
| Billions | 30.71B |
| T&R Biofab | 20.67B |
| SCL Science | 16.32B |